All In Biotech

Free tool

Medicare drug spending

CMS's Spending by Drug data: what Medicare paid for each drug before manufacturer rebates. Part D covers drugs dispensed by pharmacies; Part B covers drugs given in a doctor's office or hospital outpatient department. Commercial and list prices are not public data and are not shown.

Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations

Part D, 2024

$288.7B

Gross drug spending in the dataset

Part B, 2024

$60.8B

Gross drug spending in the dataset

Drugs listed

3

Part D and Part B

Total spending by year

  • Part D
  • Part B
View as table
YearPart DPart B
2020$194,092,038,339$37,778,829,680
2021$213,513,349,361$40,135,340,775
2022$239,779,215,689$44,241,259,745
2023$275,808,918,753$50,775,853,083
2024$288,667,842,058$60,838,164,403
Reset

Top 3 by total spending

2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.

DrugPartSpendingChangeBeneficiariesPer beneficiaryPer unit
Cimzia*

Certolizumab Pegol* · J0717

B$398M-1%25,557$15,559$4.55
Cimzia (2 Pack)

Certolizumab PEGol

D$264M+3%5,554$47,528$5,650.00
Cimzia

Certolizumab PEGol

D$19.6M+7%1,116$17,535$5,631.50

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.